Programmed cell death 1 and programmed cell death ligand 1 expression in invasive breast carcinoma using CAL10 and NAT105 immunostaining.

IF 1.6 4区 生物学 Q4 BIOTECHNOLOGY & APPLIED MICROBIOLOGY
Özlem Durak, Kemal Kürşat Bozkurt, İbrahim Metin Çiriş, Murat Kocer, Hasan Erol Eroğlu
{"title":"Programmed cell death 1 and programmed cell death ligand 1 expression in invasive breast carcinoma using CAL10 and NAT105 immunostaining.","authors":"Özlem Durak,&nbsp;Kemal Kürşat Bozkurt,&nbsp;İbrahim Metin Çiriş,&nbsp;Murat Kocer,&nbsp;Hasan Erol Eroğlu","doi":"10.1080/10520295.2022.2137586","DOIUrl":null,"url":null,"abstract":"<p><p>Increased incidence of breast cancer has stimulated development of new diagnostic and therapeutic methods. The programmed cell death 1 (PD1) pathway and its inhibitors are promising avenues for investigation. PD1 includes PD ligands 1 (PDL1) and 2 (PDL2). We investigated the expression of PD1 and PDL1 in invasive breast carcinomas using immunohistochemical staining. We used 171 invasive breast carcinoma specimens from which tissue microarray blocks were created. Immunohistochemical staining of PD1 using NAT105, and PDL1 using CAL10 was performed on tissue microarray sections. NAT105 and CAL10 are useful clones for detecting expression of PD1 and PDL1. PD1 and PDL1 immunostaining was significantly stronger in carcinomas with basal-like phenotype compared to other molecular breast cancer types. PD1 and PDL1 expression also was associated with a high histologic grade and a high Ki-67 index. PD1 expression also was associated with lymphovascular invasion and axillary metastasis. PD1 and PDL1 expression is associated with aggressive tumor behavior and a basal-like phenotype in breast cancer. We suggest that inhibition of the PD1/PDL1 pathway, particularly in triple negative breast carcinomas with basal-like phenotype, might be useful for targeted immunotherapy.</p>","PeriodicalId":8970,"journal":{"name":"Biotechnic & Histochemistry","volume":"98 2","pages":"147-154"},"PeriodicalIF":1.6000,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biotechnic & Histochemistry","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1080/10520295.2022.2137586","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Increased incidence of breast cancer has stimulated development of new diagnostic and therapeutic methods. The programmed cell death 1 (PD1) pathway and its inhibitors are promising avenues for investigation. PD1 includes PD ligands 1 (PDL1) and 2 (PDL2). We investigated the expression of PD1 and PDL1 in invasive breast carcinomas using immunohistochemical staining. We used 171 invasive breast carcinoma specimens from which tissue microarray blocks were created. Immunohistochemical staining of PD1 using NAT105, and PDL1 using CAL10 was performed on tissue microarray sections. NAT105 and CAL10 are useful clones for detecting expression of PD1 and PDL1. PD1 and PDL1 immunostaining was significantly stronger in carcinomas with basal-like phenotype compared to other molecular breast cancer types. PD1 and PDL1 expression also was associated with a high histologic grade and a high Ki-67 index. PD1 expression also was associated with lymphovascular invasion and axillary metastasis. PD1 and PDL1 expression is associated with aggressive tumor behavior and a basal-like phenotype in breast cancer. We suggest that inhibition of the PD1/PDL1 pathway, particularly in triple negative breast carcinomas with basal-like phenotype, might be useful for targeted immunotherapy.

CAL10和NAT105免疫染色在浸润性乳腺癌中程序性细胞死亡1和程序性细胞死亡配体1的表达。
乳腺癌发病率的增加刺激了新的诊断和治疗方法的发展。程序性细胞死亡1 (PD1)途径及其抑制剂是研究的重要途径。PD1包括PD配体1 (PDL1)和2 (PDL2)。我们采用免疫组化染色法研究PD1和PDL1在浸润性乳腺癌中的表达。我们使用了171例浸润性乳腺癌标本,从中创建了组织微阵列块。在组织芯片切片上用NAT105对PD1进行免疫组化染色,用CAL10对PDL1进行免疫组化染色。NAT105和CAL10是检测PD1和PDL1表达的有用克隆。pd - 1和pd - l1免疫染色在基底样表型的乳腺癌中明显强于其他分子乳腺癌类型。PD1和PDL1的表达也与高组织学分级和高Ki-67指数相关。PD1的表达也与淋巴血管侵袭和腋窝转移有关。PD1和PDL1的表达与乳腺癌的侵袭性肿瘤行为和基底样表型相关。我们认为,抑制PD1/PDL1通路,特别是在基底样表型的三阴性乳腺癌中,可能有助于靶向免疫治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Biotechnic & Histochemistry
Biotechnic & Histochemistry 生物-生物工程与应用微生物
CiteScore
3.40
自引率
6.20%
发文量
46
审稿时长
6-12 weeks
期刊介绍: Biotechnic & Histochemistry (formerly Stain technology) is the official publication of the Biological Stain Commission. The journal has been in continuous publication since 1926. Biotechnic & Histochemistry is an interdisciplinary journal that embraces all aspects of techniques for visualizing biological processes and entities in cells, tissues and organisms; papers that describe experimental work that employs such investigative methods are appropriate for publication as well. Papers concerning topics as diverse as applications of histochemistry, immunohistochemistry, in situ hybridization, cytochemical probes, autoradiography, light and electron microscopy, tissue culture, in vivo and in vitro studies, image analysis, cytogenetics, automation or computerization of investigative procedures and other investigative approaches are appropriate for publication regardless of their length. Letters to the Editor and review articles concerning topics of special and current interest also are welcome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信